GSK

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

News

GSK hails 'unprecedented' cure rates with hep B drug

The B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.

News

GSK enlists local aid for Chinese rollout of hep B drug

GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under NMPA review.

News

GSK bolts on siRNA drug from China's SiranBio in $1bn deal

GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.

News

First-quarter sales strength buoys new GSK CEO Miels

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new CEO Luke Miels.

News

GSK eyes October FDA verdict on chronic hep B drug

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK hails 'unprecedented' cure rates with hep B drug

GSK enlists local aid for Chinese rollout of hep B drug

GSK bolts on siRNA drug from China's SiranBio in $1bn deal

First-quarter sales strength buoys new GSK CEO Miels

GSK eyes October FDA verdict on chronic hep B drug

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks